WOCKHARDT
Quarterly Results Analysis [Dec2023]
WOCKHARDT Quarterly Results
Consolidated | Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
Dec2022 UnAudited |
Sep2022 UnAudited |
Jun2022 UnAudited |
Mar2022 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹701 Cr | ₹753 Cr | ₹644 Cr | ₹678 Cr | ₹699 Cr | ₹679 Cr | ₹595 Cr | ₹655 Cr |
Expenses | ₹664 Cr | ₹681 Cr | ₹628 Cr | ₹675 Cr | ₹654 Cr | ₹636 Cr | ₹611 Cr | ₹688 Cr |
Operating Income | ₹37 Cr | ₹72 Cr | ₹16 Cr | ₹3 Cr | ₹45 Cr | ₹43 Cr | ₹-16 Cr | ₹-33 Cr |
Other Income | ₹8 Cr | ₹24 Cr | ₹14 Cr | ₹32 Cr | ₹2 Cr | ₹57 Cr | ₹57 Cr | ₹14 Cr |
Interest | ₹77 Cr | ₹76 Cr | ₹79 Cr | ₹76 Cr | ₹83 Cr | ₹70 Cr | ₹73 Cr | ₹86 Cr |
Depreciation | ₹55 Cr | ₹55 Cr | ₹55 Cr | ₹56 Cr | ₹66 Cr | ₹65 Cr | ₹64 Cr | ₹59 Cr |
Profit Before Tax | ₹-87 Cr | ₹-35 Cr | ₹-118 Cr | ₹-193 Cr | ₹-105 Cr | ₹-230 Cr | ₹-96 Cr | ₹-347 Cr |
Profit After Tax | ₹-86 Cr | ₹-73 Cr | ₹-136 Cr | ₹-237 Cr | ₹-102 Cr | ₹-207 Cr | ₹-75 Cr | ₹-311 Cr |
EPS | ₹-5.76 | ₹-5.35 | ₹-9.31 | ₹-14.44 | ₹-6.67 | ₹-13.13 | ₹-4.65 | ₹-17.92 |
Industry Peers & Returns | 1W | 1M | 1Y |
WOCKHARDT | -2.4% | 4.2% | 231.5% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
CIPLA | 4.5% | -3.1% | 52.8% |
DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
MANKIND PHARMA | 2.7% | 12.4% | NA |
TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
LUPIN | 3.1% | -1.1% | 127.4% |
WOCKHARDT Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -6.91 % |
Y-o-Y | 0.29 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2023 | ₹701 Cr | -6.91 | |
Sep2023 | ₹753 Cr | 16.93 | |
Jun2023 | ₹644 Cr | -5.01 | |
Mar2023 | ₹678 Cr | -3.00 | |
Dec2022 | ₹699 Cr | 2.95 | |
Sep2022 | ₹679 Cr | 14.12 | |
Jun2022 | ₹595 Cr | -9.16 | |
Mar2022 | ₹655 Cr | - |
WOCKHARDT Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -48.61 % |
Y-o-Y | -17.78 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2023 | ₹37 Cr | -48.61 | |
Sep2023 | ₹72 Cr | 350.00 | |
Jun2023 | ₹16 Cr | 433.33 | |
Mar2023 | ₹3 Cr | -93.33 | |
Dec2022 | ₹45 Cr | 4.65 | |
Sep2022 | ₹43 Cr | Positive | |
Jun2022 | ₹-16 Cr | Negative | |
Mar2022 | ₹-33 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -44.77 % |
Y-o-Y | -18.01 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2023 | 5.28% | -44.77 | |
Sep2023 | 9.56% | 285.48 | |
Jun2023 | 2.48% | 463.64 | |
Mar2023 | 0.44% | -93.17 | |
Dec2022 | 6.44% | 1.74 | |
Sep2022 | 6.33% | Positive | |
Jun2022 | -2.69% | Negative | |
Mar2022 | -5.04% | - |
WOCKHARDT Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2023 | ₹-86 Cr | Negative | |
Sep2023 | ₹-73 Cr | Negative | |
Jun2023 | ₹-136 Cr | Negative | |
Mar2023 | ₹-237 Cr | Negative | |
Dec2022 | ₹-102 Cr | Negative | |
Sep2022 | ₹-207 Cr | Negative | |
Jun2022 | ₹-75 Cr | Negative | |
Mar2022 | ₹-311 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2023 | -12.27 % | Negative | |
Sep2023 | -9.69 % | Negative | |
Jun2023 | -21.12 % | Negative | |
Mar2023 | -34.96 % | Negative | |
Dec2022 | -14.59 % | Negative | |
Sep2022 | -30.49 % | Negative | |
Jun2022 | -12.61 % | Negative | |
Mar2022 | -47.48 % | - |
WOCKHARDT Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | Negative |
Y-o-Y | Negative |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2023 | ₹-5.76 | Negative | |
Sep2023 | ₹-5.35 | Negative | |
Jun2023 | ₹-9.31 | Negative | |
Mar2023 | ₹-14.44 | Negative | |
Dec2022 | ₹-6.67 | Negative | |
Sep2022 | ₹-13.13 | Negative | |
Jun2022 | ₹-4.65 | Negative | |
Mar2022 | ₹-17.92 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs MANKIND PHARMA LTD